Divalproex Sodium Tablet, Delayed Release
Product Images NDC 29300-140

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 29300-140). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unichem Pharmaceuticals (usa), Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

39cef9df 868d 4963 B0a7 7f146275442f 01

Chemical structure of Divalproex Sodium displayed in the image as a repeated unit polymer. The structure shows sodium ions, carbon chains, and associated functional groups typical for this compound.*

FDA Label Image

39cef9df 868d 4963 B0a7 7f146275442f 02

A bar chart comparing two studies measuring percentages for PBO and DVPX groups. Study 1 (years) shows 26% for PBO and 60% for DVPX. Study 2 (months) shows 29% for PBO and 58% for DVPX.*

FDA Label Image

39cef9df 868d 4963 B0a7 7f146275442f 03

A cumulative percentage response curve graph comparing Divalproex Sodium delayed-release tablets with placebo. The x-axis shows the percentage of patients, and the y-axis shows the percentage reduction in CPS rate, indicating improvement or worsening. Solid and dashed lines represent Divalproex Sodium and placebo, respectively.*

FDA Label Image

39cef9df 868d 4963 B0a7 7f146275442f 04

A line graph showing the percentage reduction in CPS rate on the vertical axis and the percentage of patients on the horizontal axis. The graph compares the effects of high dose and low dose treatments, with an upward trend indicating improvement and a downward trend indicating worsening.*

FDA Label Image

39cef9df 868d 4963 B0a7 7f146275442f 05

This chart compares numerical data between placebo and Divalproex Sodium groups in two separate studies, labeled Study 1 and Study 2. Each study shows two bars representing the placebo and Divalproex Sodium groups, with a vertical axis measuring values up to 6. The chart visually represents comparative outcomes between treatments.*

FDA Label Image

39cef9df 868d 4963 B0a7 7f146275442f 06

FDA Label Image

39cef9df 868d 4963 B0a7 7f146275442f 07

Label for Divalproex Sodium delayed release tablets, USP, 125 mg strength. The label indicates 100 tablets per container and highlights valproic acid activity. Manufactured by Unichem Laboratories Ltd., India, for Unichem Pharmaceuticals (USA), Inc., East Brunswick, NJ. Storage instructions specify 20° to 25°C. The NDC number 29300-138-01 is displayed prominently.*

FDA Label Image

39cef9df 868d 4963 B0a7 7f146275442f 08

Label for Divalproex Sodium delayed release tablets, USP 250 mg. The oral tablet is prescription only and comes in a package containing 100 tablets. The label lists storage instructions, drug content, and dispensing guidance. Manufactured by Unichem Laboratories Ltd., India, and labeled by Unichem Pharmaceuticals (USA), Inc.*

FDA Label Image

39cef9df 868d 4963 B0a7 7f146275442f 09

Label for Divalproex Sodium Delayed Release Tablets USP, 500 mg, oral dosage form. The label includes storage instructions (20° to 25°C), dispensing guidelines, and a barcode. It states the product contains Divalproex Sodium equivalent to 500 mg Valproic acid per tablet. Manufactured by Unichem Laboratories Ltd., India, and labeled for Unichem Pharmaceuticals (USA), Inc. The package count is 100 tablets, with Rx only restriction.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.